studies

HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) AASLD ABSTRACTS 1263A
0.84), 0.84(0.76-0.92) and 0.88(0.82-0.94), respectively.
NFS had the highest NPV (98%), while NPVs of AAR, APRI,
BARD and FIB-4 were 87%, 85%, 94.5% and 94%, respectively.
56% to 83% of cohort 1 pts were correctly classified as
having or not AF. In cohort 2 (mean age 46±13, males 65%,
diabetes 28%, mean BMI 30±5, AF 23.5%), AUROCs of AAR,
APRI, BARD, FIB-4 and NFS were 0.58(0.50-0.66), 0.55(0.47-
0.63), 0.64(0.57-0.71), 0.68(0.61-0.75) and 0.66(0.59-
0.73), respectively. NFS had the highest NPV (84%), while
NPVs of AAR, APRI, BARD and FIB-4 were 78%, 77.5%, 83%
and 82%. 64% to 71% of cohort 2 pts were correctly classified
as having or not AF. In cohort 3 (mean age 49±13, males
61%, diabetes 38%, mean BMI 31±5, AF 22.7%), AUROCs
of AAR, APRI, BARD, FIB-4 and NFS were 0.65(0.58-0.71),
0.73(0.67-0.79), 0.71(0.65-0.76), 0.74(0.68-0.8) and
0.71(0.65-0.77), respectively. BARD had the higher NPV
(89%), while NPVs of AAR, APRI, FIB-4 and NFS were 84%,
81%, 88% and 86%. 61% to 78% of cohort 3 pts were correctly
classified as having or not AF. Conclusions: There is a
substantial variability across different cohorts in the diagnostic
accuracy of non-invasive scoring systems for ruling-out AF in
NAFLD. Complex scores (BARD, FIB-4, NFS) perform better
than simple ones (AAR and APRI), but none of them is consistently
within the acceptable range for clinical-decision making
in an individual patient. Combination with imaging methods
should be tested in future studies.
Disclosures:
Manuel Romero-Gomez - Advisory Committees or Review Panels: Roche Farma,SA.,
MSD, S.A., Janssen, S.A., Abbott, S.A.; Grant/Research Support: Ferrer,
S.A.
Giulio Marchesini - Advisory Committees or Review Panels: Sanofi-Synthelabo;
Board Membership: GENFIT, Gilead, Glaxo, Novartis; Grant/Research Support:
Merck Sharp & Dome; Speaking and Teaching: Novo Nordisk, Merck Sharp &
Dome, Boerhinger Ingelheim, Eli Lilly, Astra-Zeneca
Michael Trauner - Advisory Committees or Review Panels: MSD, Janssen, Gilead,
Abbvie; Consulting: Phenex; Grant/Research Support: Intercept, Falk Pharma,
Albireo; Patent Held/Filed: Med Uni Graz (norUDCA); Speaking and Teaching:
Falk Foundation, Roche, Gilead
Jean-Francois Dufour - Advisory Committees or Review Panels: Bayer, BMS, Gilead,
AbbVie, Novartis, Sillagen, Genfit
Vlad Ratziu - Advisory Committees or Review Panels: GalMed, Abbott, Genfit,
Enterome, Gilead; Consulting: Tobira, Intercept, Exalenz, Sanofi-Synthelabo,
Boehringer-Ingelheim
The following authors have nothing to disclose: Fabio Nascimbeni, Salvatore
Petta, Elisabetta Bugianesi, Stefano Bellentani, Christopher P. Day, Pierre
Bedossa, Claudia P. Oliveira, Raluca Pais
2165
DJ-1 labeling index is a novel diagnostic biomarker for
predicting progression of nonalcoholic steatohepatitis
Masaaki Takamura 1 , Satoshi Yamagiwa 1 , Yasunobu Matsuda 2 ,
Minoru Nomoto 1 , Toshifumi Wakai 1 , Shuji Terai 1 ; 1 Niigata University
Graduate School of Medical and Dental Sciences, Niigata,
Japan; 2 Niigata University Graduate School of Health Sciences,
Niigata, Japan
Background & Aims: Nonalcoholic steatohepatitis (NASH) is
a common cause of chronic liver disease that can progress to
cirrhosis and hepatocellular carcinoma. We have previously
reported that hepatic proteins that were dysregulated in a
murine NASH model functioned in a wide variety of pathways,
including oxidative stress, glycolysis, the urea cycle, fatty acid
oxidation, and apoptosis, based on a proteomic approach.
Among the candidate proteins, we focused on the antioxidant
protein DJ-1, which was upregulated in the livers of NASH
model mice. In this study we analyzed the clinical implications
of DJ-1 in patients with NASH. Methods: Liver biopsies and
blood samples were obtained from 72 and 38 patients with
nonalcoholic fatty liver disease (NAFLD) and 8 and 16 control
subjects, respectively. The hepatic DJ-1 expression and serum
DJ-1 levels were investigated using immunohistochemistry and
enzyme-linked immunosorbent assay, respectively. The percentage
of immunoreactive hepatocyte nuclei in the total number
of hepatocyte nuclei was defined as DJ-1 labeling index (LI).
NASH was assessed according to the Brunt classification.
Results: DJ-1 was localized in the hepatocyte cytoplasm in the
control and was incrementally translocated to the nucleus in
NAFLD. A stepwise increase in DJ-1 LI (median [interquartile
range]) was found from the control group (0 % [0-0.16]) to the
nonalcoholic fatty liver (NAFL) group (4.34 % [1.50-15.4]) to
the NASH group (38.5 % [29.6-48.7]; p